FDA approves Rukobia for HIV

The Food and Drug Administration has green-lighted ViiV Healthcare’s Rukobia (fostemsavir).

The medication offers a new antiretroviral treatment for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.

"This approval marks a new class of antiretroviral medications that may benefit patients who have run out of HIV treatment options," said Jeff Murray, deputy director of the Division of Antivirals in the FDA's Center for Drug Evaluation and Research.

Murray added, "The availability of new classes of antiretroviral drugs is critical for heavily treatment-experienced patients living with multidrug-resistant HIV infection—helping people living with hard-to-treat HIV who are at greater risk for HIV-related complications, to potentially live longer, healthier lives."